Immunogenicity after COVID-19 vaccines in adapted schedules (IMCOVAS). 26/05/2021 - 11/02/2023

Abstract

Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vaccine (COVID-19 Vaccine Moderna®; Moderna) and COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria®, AstraZeneca). A A prospective, post marketing, randomized, partially single blind, multicenter, interventional study in 560 healthy adults 18-55y Most important exclusion criteria: • Confirmed previous covid-19-infection • Previous covid-19 vaccination Study will be carried out in 4 study centres, specialised in vaccination trials, in Belgium. Intervention: Vaccines: • BNT162b2: 30 mcg (IM), 20 mcg (IM) and 6mcg (ID) • mRNA-1273 Vaccine : 100mcg (IM) and 50mc (IM) • COVID-19 Vaccine (ChAdOx1-S [recombinant])

Researcher(s)

Research team(s)

Project type(s)

  • Research Project